Acadia Pharmaceuticals reported $1.79B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
ALKERMES USD 4.44B 42.4M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Cara Therapeutics USD 23.53M 2.28M Sep/2026
Corcept Therapeutics USD 1.03B 145.32M Sep/2026
Cytokinetics USD 1.82B 99.77M Sep/2026
Eisai JPY 1.52T 33.49B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Moderna USD 13.47B 2.51B Sep/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Prothena USD 283.52M 19.06M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026